Minimal Priapism Risk with AndroGel 1% Use

Share this article:

Testosterone replacement with 1% testosterone gel (AndroGel 1%) is rarely associated with the development of priapism, according to a study.

Arthur L. Burnett, MD, of Johns Hopkins University in Baltimore, and colleagues reviewed the safety and tolerability data for AndroGel 1%, including data from three randomized controlled trials in varying populations of hypogonadal or near hypogonadal men. Of  283 men exposed to AndroGel 1% over the three trials, none reported experiencing adverse events described as priapism or related symptoms, researchers reported online ahead of print in the Journal of Sexual Medicine. The investigators also reviewed postmarketing data representing 40 million units sold and found only eight reports of cases described as priapism.

The researchers concluded from their findings that AndroGel 1% use is associated with a minimal risk of inducing priapism.

Share this article:
You must be a registered member of RUN to post a comment.

More in Hypogonadism

FDA Panel: Limit Testosterone Drug Use

FDA Panel: Limit Testosterone Drug Use

Joint committee also calls for drug makers to run heart-risk tests on popular 'Low T' products.

Insufficient Data on Benefits, Risks of Testosterone Drugs

Insufficient Data on Benefits, Risks of Testosterone Drugs

Expert panel to decide whether prescribing information on testosterone drugs should be changed.

Common Chemicals Lower Testosterone

Common Chemicals Lower Testosterone

Chemicals found in many household products may reduce androgen levels in both sexes.